N5-(二氨基亚甲基)-L-鸟氨酸(2Z)-2-丁烯二酸酯(1:1) | 93778-36-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N5-(二氨基亚甲基)-L-鸟氨酸(2Z)-2-丁烯二酸酯(1:1)
• 英文名称: L-Arginine maleate
• 英文别名: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(Z)-but-2-enedioic acid
• CAS: 93778-36-0
• 化学式: C10H18N4O6
• 分子量: 290.27
• InChiKey: VNFMIHBKZKZIQO-HSBCLPKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.84
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  202
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• Drug for the effective control of acute and or chronic pain and a method for its administration
  申请人：PVP LABS PTE. LTD.

  公开号：US10357533B2

  公开（公告）日：2019-07-23

  The proposed drug relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including the late stages of cancer. The stated means is based on a compound for preventing and/or treating acute or chronic pain in a subject, including an analgesic peptide having an amino acid sequence H-Tyr-D-Arg-Phe-Gly-NH2 or an amino acid sequence H-Tyr-D-Arg-Phe-Sar-OH. Also, a method of use/administration of the compound for the prevention and/or treatment of acute and/or chronic pain is disclosed.

  拟议的药物涉及医药和兽医应用，特别是作为有效控制急性和/或慢性疼痛的手段，可用于急诊治疗急性和/或慢性疼痛，包括癌症晚期。所述方法基于一种用于预防和/或治疗受试者急性或慢性疼痛的化合物，包括一种镇痛肽，其氨基酸序列为H-Tyr-D-Arg-Phe-Gly-NH2或H-Tyr-D-Arg-Phe-Sar-OH。此外，还公开了该化合物用于预防和/或治疗急性和/或慢性疼痛的使用/给药方法。
• AN L-ARGININE-BASED FORMULATION FOR ORAL ABSORPTION
  申请人：Geshuri, Benzion

  公开号：EP2369925A1

  公开（公告）日：2011-10-05
• L-ARGININE-BASED FORMULATION FOR ORAL ABSORPTION
  申请人：Geshuri Benzion

  公开号：US20110236508A1

  公开（公告）日：2011-09-29

  A formulation comprising large quantities of l-arginine and/or fat plaque dissolving agents which is palatable, stench free, and does not evoke nausea. The formulation is adapted to facilitate the adsorption of l-arginine to the blood system and to introduce high levels of l-arginine and/or other fat plaque dissolving agents such as EDTA, its derivatives or its salts into the blood system which are sufficient for effectively dissolving fat plaques in the artery. The formulation comprises at least 10% (w/w) L-arginine, edible organic acids, emulsifier(s), preservatives, flavorings, ethanol and water. Other embodiments may further include chromium salts, and EDTA or its derivatives and their salts
• [EN] AN L-ARGININE-BASED FORMULATION FOR ORAL ABSORPTION<br/>[FR] FORMULATION À BASE DE L-ARGININE S'ADMINISTRANT PAR VOIE ORALE
  申请人：GESHURI BENZION

  公开号：WO2010061395A1

  公开（公告）日：2010-06-03

  A formulation comprising large quantities of l-arginine and/or fat plaque dissolving agents which is palatable, stench free, and does not evoke nausea. The formulation is adapted to facilitate the adsorption of l-arginine to the blood system and to introduce high levels of l-arginine and/or other fat plaque dissolving agents such as EDTA, its derivatives or its salts into the blood system which are sufficient for effectively dissolving fat plaques in the artery. The formulation comprises at least 10% (w/w) L-arginine, edible organic acids, emulsifier(s), preservatives, flavorings, ethanol and water. Other embodiments may further include chromium salts, and EDTA or its derivatives and their salts.